Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: Cancer Prev Res (Phila). 2017 Nov 22;11(2):113–119. doi: 10.1158/1940-6207.CAPR-17-0245

Table 1.

Clinicopathologic characteristics

Overall
N = 258
KTB
n = 86
BBD controls
n = 86
BBD cases
n = 86
Age
 <45 48 (18.6%) 16 (18.6%) 16 (18.6%) 16 (18.6%)
 45–55 96 (37.2%) 35 (40.7%) 30 (34.9%) 31 (36.0%)
 >55 114 (44.2%) 35 (40.7%) 40 (46.5%) 39 (45.3%)
BMI
 Not available 8 0 5 3
 <25 86 (34.4%) 24 (27.9%) 32 (39.5%) 30 (36.1%)
 25–29 88 (35.2%) 30 (34.9%) 25 (30.9%) 33 (39.8%)
 ≥30 76 (30.4%) 32 (37.2%) 24 (29.6%) 20 (24.1%)
Lobular involution
 Not available 12 3 1 8
 None 36 (14.6%) 4 (4.8%) 12 (14.1%) 20 (25.6%)
 Partial 114 (46.3%) 35 (42.2%) 37 (43.5%) 42 (53.8%)
 Complete 96 (39.0%) 44 (53.0%) 36 (42.4%) 16 (20.5%)
Histologic impression
 Not available 2 2 0 0
 No histologic abnormality 54 (21.1%) 54 (64.3%) 0 0
 Nonproliferative disease 79 (30.9%) 22 (26.2%) 34 (39.5%) 23 (26.7%)
 Proliferative disease without atypia 87 (34.0%) 7 (8.3%) 38 (44.2%) 42 (48.8%)
 Atypia 36 (14.1%) 1 (1.2%) 14 (16.3%) 21 (24.4%)